ArticleFrontiers in surgery2026
Case Report: First case of synchronous androgen receptor-positive salivary duct carcinoma and prostate adenocarcinoma.
Article in Frontiers in surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The synchronous occurrence of two androgen receptor-positive (AR+) malignancies with overlapping metastatic patterns is exceedingly rare and poses significant diagnostic and therapeutic challenges. Salivary duct carcinoma (SDC) is an aggressive AR + tumor with a high propensity for early metastasis, whereas low-risk prostate adenocarcinomas (PCa) are often indolent. We report the first case of a synchronous SDC of the right parotid gland and a low-grade PCa, where the origin of osseous metastatic spread was initially unknown. Case presentation: A 65-year-old male patient presented with progressive right-sided facial palsy and multiple osseous lesions. Initial histopathological assessment of the parotid mass and assignment of the metastases remained inconclusive. After performing a prostate-specific membrane antigen-positron emission tomography/computed tomography (PSMA-PET-CT) scan, a low-grade prostate adenocarcinoma (PCa) (Gleason 3 + 3) was diagnosed. Further pathological and imaging evaluation revealed an AR+, HER2-low, CK7-positive SDC. The extensive skeletal metastases were attributed to the SDC. Conclusion: This case shows the diagnostic complexity of synchronous AR + malignancies with overlapping metastatic profiles and emphasizes the need for integrated clinical, radiological, and pathological assessment to ensure optimal patient management. It highlights the need to biopsy metastatic bone lesions in cases of SDC-especially in older men-to rule out osseous metastases from more frequent carcinomas such as PCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.